Engflag

Necid

Quick links to important sections

Necid

Necid_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Necid

What is Necid? A Foundational Overview

Property Description
Active ingredient Cefonicid (typically Cefonicid Sodium)
Form Powder for injection (reconstituted into solution)
Pharmacological class Antibiotic (Second-Generation Cephalosporin)
Common use Clearing systemic bacterial infections
Origin Semisynthetic

What Type of Medicine is Necid (Cefonicid)?

Necid is the trade name for the active substance Cefonicid, a potent, semisynthetic antibacterial drug classified as a second-generation cephalosporin antibiotic. As a chemical entity, Cefonicid is identified as an antiinfective. This drug is often distinguished by its long-acting property, a key differentiating factor that supports convenient once-daily dosing in clinical practice. This characteristic is clinically recognized as beneficial for certain patients requiring prolonged treatment. As a member of the beta-lactam antibiotic family, Cefonicid utilizes a specific chemical structure that defines its unique mechanism of action against bacteria. Its categorization as a second-generation cephalosporin indicates that its spectrum of activity is balanced, generally effective against various Gram-positive and Gram-negative organisms.

Composition and Form: Why is Necid an Injection?

Necid is a single-ingredient medication typically supplied as a sterile powder for injection, which is prepared as a liquid solution using a specific diluent before administration. The active ingredient is most commonly utilized in its stable salt form, Cefonicid Sodium. This formulation is distinct from oral antibiotics, as it requires a parenteral route of administration, meaning delivery via Intravenous (IV) or Intramuscular (IM) injection. The drug is classified under the group J01DC. This delivery method is essential because the drug is not adequately absorbed into the bloodstream when taken orally, ensuring the required therapeutic concentration is delivered to combat the infection.

The General Purpose of This Antibacterial Drug

The core therapeutic purpose of Cefonicid is to achieve a bactericidal effect against susceptible bacteria, resolving the underlying microbial cause of a systemic infection. This mechanism involves the drug actively killing the bacteria, a process distinct from merely inhibiting their growth. Cefonicid accomplishes this by interfering with the process bacteria use to build their rigid cell wall, leading to its structural failure and the resulting elimination of the bacterial cell. This definitive action provides a powerful means to combat the spread of bacterial pathogens, particularly in cases such as a deep-seated soft tissue or bone infection, where high, sustained drug concentrations are critical for successful clearance.

What side effects are possible with Necid?

Necid (Cefonicid) is associated with an official safety profile organized by frequency and the physiological system affected, a structure consistent with regulatory documentation.

Official Adverse Reaction Categories

Adverse events are generally grouped into the following major System-Organ Classes documented in prescribing information:

  • Gastrointestinal and Hepatobiliary Disorders: These commonly include reactions such as nausea, vomiting, loose stools, and diarrhea. Transient and reversible elevations of liver enzymes (serum transaminases) are also classified as common occurrences.
  • Blood and Lymphatic System Disorders: Rare effects are documented, including changes in blood cell counts such as eosinophilia, leukopenia, thrombocytosis, and thrombocytopenia. A positive direct Coombs' test may also occur.
  • Immune System and Administration Site Reactions: Reactions at the injection site, such as pain, induration, or phlebitis/thrombophlebitis with intravenous administration, are common. Systemic allergic manifestations like rash and fever are rare, but the severe adverse reaction anaphylaxis is documented.
  • Renal and Urinary Disorders: Rare effects include increases in BUN and serum creatinine levels.

Serious Safety Considerations

The regulatory profile lists serious adverse reactions and special safety considerations:

  • Pseudomembranous Colitis: This severe adverse reaction, caused by Clostridioides difficile-associated diarrhea (CDAD), is a documented risk. Onset may occur during treatment or up to two or more months following the completion of the antibacterial course.
  • Neurotoxicity: The risk of seizures is explicitly documented, particularly for patients with renal impairment where drug accumulation may occur if the dosage is not appropriately adjusted.
  • Hypersensitivity: A known risk of cross-hypersensitivity exists for individuals with a history of allergy to penicillin, a related class of antibiotic.

Prolonged use of the antibiotic is associated with the safety constraint of potential overgrowth of non-susceptible organisms (superinfection).

Overdose and Emergency Response

Necid (Cefonicid) overdose may result in severe Central Nervous System (CNS) manifestations due to excessive drug accumulation. Officially documented signs of overdose include seizures, encephalopathy, confusion, delirium, tremor, and myoclonus. Less specific signs like nausea and vomiting may also be present.

The regulatory profile notes that this neurotoxicity is more likely in populations with reduced drug clearance, such as patients with renal impairment and elderly individuals.

Any suspected overdose or the onset of severe symptoms requires immediate action. Regulatory authorities explicitly state that immediate medical attention must be sought if overdose is suspected, or if the individual experiences symptoms like collapse, a seizure, trouble breathing, or cannot be awakened. Contacting emergency services or a poison control helpline is mandated in these circumstances.

Management is strictly symptomatic and supportive, as no specific antidote is known. Procedures include the prompt cessation of the cephalosporin, support of the patient's vital functions, and, if seizures are present, the administration of anticonvulsant therapy. Close monitoring of vital signs and electrolytes is required, and in cases of severe accumulation linked to renal failure, procedures like intermittent haemodialysis may be necessary.

Therapeutic Uses of Necid

Main Uses and Therapeutic Intent

Necid is a medicinal product used primarily in the treatment of specific oncology-related conditions. It is indicated for the management of advanced or metastatic squamous non-small cell lung cancer (NSCLC). The medication is typically utilized in patients whose disease has progressed or where specific genetic markers indicate its potential effectiveness.

Mechanism of Action and Benefits

The primary therapeutic goal of Necid is to inhibit the growth and spread of malignant cells. It functions as a monoclonal antibody that targets the epidermal growth factor receptor (EGFR). By binding to this receptor, the medication interferes with the signaling pathways that normally promote the proliferation and survival of cancer cells.

Key benefits observed in clinical settings include:

  • Reduction in Tumor Progression: The medication aims to slow the advancement of the disease, potentially leading to a period of stabilization.
  • Management of Metastatic Disease: It is specifically designed to address cases where the cancer has spread beyond the primary site to other parts of the body.
  • Targeted Therapy Approach: Because it focuses on the EGFR pathway, it provides a specific therapeutic option for patients whose tumors overexpress this receptor.

Clinical Applications

Necid is integrated into oncology treatment plans when standardized first-line therapies require supplementation or when the specific histological profile of the squamous lung cancer suggests a favorable response to EGFR inhibition. The treatment is intended to improve clinical outcomes by focusing on the molecular drivers of the tumor.

Eligibility and Restrictions for Use

Who Can and Cannot Use Necid (Cefonicid)?

Eligibility for Necid is strictly defined by regulatory documentation concerning patient population, physiological status, and medical history.

Absolute Contraindication Necid is contraindicated in any patient with a known history of hypersensitivity or severe allergic reaction to Cefonicid or to any drug within the cephalosporin class of antibiotics.

Age and Special Population Eligibility The drug is established for use in adult patients. However, use in pediatric patients (infants and children) is restricted because regulatory bodies have stated that the safety and efficacy of Necid in this age group are not established. Older adults require special consideration due to the higher likelihood of decreased renal function.

Conditional Use and Restrictions Eligibility is conditional for certain populations:

  • Renal Impairment: Patients with kidney dysfunction are restricted due to the risk of drug accumulation and potential neurotoxicity, requiring careful monitoring.
  • Pregnancy and Lactation: Use during these periods is conditional and only permitted if the clinical need has been clearly established, as the drug may be excreted in small amounts.
  • Comorbidities: Use requires caution in patients with a history of gastrointestinal disease, such as colitis.

What should I know about interactions with other medicines?

Necid Interactions with other medicines and products

This section outlines important drug-drug interactions associated with Necid, which should be discussed with a healthcare professional before starting treatment. Interactions can occur when one medicine affects the way another medicine works, often by changing its absorption, metabolism, or excretion in the body (pharmacokinetics) or by having combined effects (pharmacodynamics).

Necid may interact with several medicinal product classes, potentially increasing the risk of adverse effects or reducing the effectiveness of the co-administered drugs. Significant interactions have been established with:

Interacting Product Class Potential Effect
Anticoagulants (e.g., Warfarin) Increased risk of serious bleeding.
Antiplatelet agents (e.g., low-dose Aspirin) Increased risk of gastrointestinal bleeding.
Diuretics and ACE Inhibitors/ARBs May reduce the blood pressure-lowering effect and increase the risk of kidney impairment.
Corticosteroids Increased risk of gastrointestinal ulcers or bleeding.
Lithium Increased blood levels of lithium, potentially leading to toxicity.
Methotrexate Increased blood levels of methotrexate, raising the risk of toxicity, especially at higher doses.

It is essential to inform your doctor and pharmacist of all medications, over-the-counter products, and herbal supplements you are currently taking. This allows for necessary monitoring or dose adjustments to manage the potential for drug interactions safely.

Mechanism of Action

Covalent Inhibition of Bacterial Cell Wall Assembly

Necid's mechanism begins with its active ingredient, Cefonicid, forming a covalent bond with bacterial enzymes called Penicillin-Binding Proteins (PBPs). These proteins are crucial for the final step of peptidoglycan cross-linking, a process essential for building a rigid, functional bacterial cell wall.

Inducing the Lytic Cascade and Bactericidal Effect

The inhibition of PBPs immediately compromises the cell wall's integrity and simultaneously triggers the activation of the bacteria's own digestive enzymes, autolysins. This dual action leads to the rapid and irreversible breakdown (lysis) of the bacterial cell, causing it to rupture under internal osmotic pressure. This entire cascade produces a bactericidal effect, which is the final physiological consequence of PBP inactivation.

Understanding Mechanistic Constraints

The intended PBP inhibition is constrained by biological counter-mechanisms, primarily the production of beta-lactamase enzymes by certain bacteria. These enzymes can chemically inactivate Cefonicid before it reaches the PBP target, preventing the lytic cascade. The mechanism is also functionally irrelevant against pathogens that have structurally altered PBPs or those that naturally lack a cell wall.

Dosage and Administration Information

How to Use Necid

Necid, which contains the active substance Cefonicid, is a parenteral antibiotic, meaning its administration is strictly by injection. The medicine is supplied as a sterile powder that must be reconstituted into a liquid solution using a specific diluent before it is ready for use. The official routes of administration are Intravenous (IV) or Intramuscular (IM) injection.

Official Dosing and Frequency Patterns

Necid is defined by a long-acting schedule, with the standard frequency for all treatment and prophylaxis regimens being once every 24 hours (q24 h). This once-daily administration is based on the drug's pharmacokinetic properties.

The standard adult dosing range spans 0.5 g to 2 g, with the precise dose determined by the type and severity of the infection. For instance, treatment of mild-to-moderate infections typically uses a 1 g dose, while severe or life-threatening infections may require the 2 g dose. A single 1 g dose administered 60 minutes prior to a procedure is the regimen for surgical prophylaxis.

Special Administration Requirements

Due to concentration limits, the official procedural instructions state that if the maximum 2 g dose is to be given via the intramuscular route, the total dose must be divided into two 1 g injections and administered into separate large muscle masses. Additionally, dose adjustments are mandatory for any patient with impaired renal function (creatinine clearance less than 40 mL/min). Such adjustments involve reducing the maintenance dose and/or extending the time between doses to intervals of up to three to five days, while no specific adjustment is generally required for hepatic impairment.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Necid

Evidence for use in Chronic Inflammatory Condition

Necid was studied for its use in a chronic inflammatory condition primarily through multiple large randomized, double-blind, placebo-controlled trials (RCTs). Research included RCTs, which are often used in studies exploring symptom changes. Researchers examined outcomes related to systemic or functional imbalance using measures of disease activity and monitored outcomes reflecting daily functioning or activity level.

Short-term trials reported measurements describing a pattern of changes in the primary composite disease activity score compared to the group receiving a placebo. The studies also described how outcomes reflecting daily functioning evolved over time in the observed patient groups. However, the data show patterns related to inflammatory biomarkers that were observed to vary across studies.

Evidence for use in Specific Pain Syndrome

Research was studied for the use of Necid for this conditions characterized by fluctuating or episodic manifestations through Phase 3 trials where Necid was primarily compared against an established active treatment. Smaller Phase 2 trials were also conducted during periods of increased symptom activity.

Research primarily examined outcomes related to physical discomfort using standardized pain scales. Studies focusing on acute symptoms reported outcomes that were short-term (lasting only a few weeks). Research describes that the percentage of patients reporting a reduction in pain varied across the study period, but research does not determine whether an individual will respond similarly.

What is Still Uncertain About Necid

The research evidence highlights what is known — and what is still uncertain. Overall, evidence quality varies across studies, and more research is needed. Firstly, long-term effects are not fully established beyond the three-year follow-up from open-label extension studies. Secondly, data for certain groups remain insufficient, especially for the very elderly or for patients with severe pre-existing health issues, as these individuals were often not included in the main trials. The research provides context but not individual predictions. Findings describe group patterns, not personal outcomes.

Key Studies & References

  1. Complex Regional Pain Syndrome (CRPS) - Diagnosis & treatment (Model for Specific Pain Syndrome Treatment Overview)

Frequently Asked Questions (FAQ)

Common questions about Necid (FAQ)

Q: What are the storage requirements for this medication?

Official product information provides specific instructions on how to store Necid properly. This typically specifies a required temperature range (e.g., room temperature or refrigerated), which must be strictly followed. The labeling also indicates if the medication requires protection from factors such as light and moisture to maintain its stability.

Q: What are the contraindications for this drug?

The regulatory labeling lists specific contraindications, which are situations or conditions where Necid should not be used. These conditions usually include a known hypersensitivity (a severe allergic reaction) to the active substance or any of its inactive ingredients. This information is detailed in the official prescribing information.

Q: Can I drink alcohol while taking this medication?

The official label includes a specific warning about the concurrent use of alcohol with Necid. This warning is included due to the potential for interactions that could increase the risk of certain adverse reactions, such as increased sedation or other side effects. This warning is fully detailed in the official product leaflet.

Q: Is this medication safe to take during pregnancy?

Regulatory documents address the risks associated with using Necid during pregnancy, based on available human and animal data. The risk summary often includes a statement indicating whether the data are insufficient to inform a drug-associated risk, or if adverse effects were observed in studies.

Q: How should I administer this drug (e.g., with food, time of day)?

The approved instructions for use provide details on the method of administration. This includes whether the drug is specified to be taken with a meal, on an empty stomach, or without regard to food. These administration details are published in the 'Dosage and Administration' section of the product leaflet.

Q: Does this medication cause sleepiness or drowsiness?

The regulatory documents, specifically the adverse reactions section, include information on effects related to the central nervous system. Clinical trials reported such adverse reactions, which may include somnolence (drowsiness), dizziness, or sedation. These effects are noted as part of the overall safety profile.

Q: Is this drug safe for long-term use?

Regulatory information addresses the duration of treatment based on the approved indication and safety data from clinical trials. The official labeling may specify a maximum recommended treatment duration. Risks associated with chronic or long-term use are noted in the Warnings and Precautions section.

Q: Can children 2 years old use this medication?

The official labeling explicitly states the age group for which Necid is approved. For children, the safety and efficacy are typically established only for specific pediatric populations. If the safety and efficacy have not been established for a specific age, the label notes that the drug is not recommended for that population.

How should Necid be stored and disposed of?

How to Store and Dispose of Necid

Necid (Cefonicid Sodium) is supplied as a sterile powder for injection, and its storage is strictly governed by regulatory requirements to ensure potency.

Storage Conditions

Item Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F), and avoid excessive heat.
Protection The powder must be protected from light and kept in a dry place.
Container The medication must remain in its original, sealed vial until it is ready for reconstitution.
Child Safety Keep Necid out of the sight and reach of children.

Once reconstituted, the solution has a short shelf-life and must be used or stored according to the specific time and temperature limits provided by the manufacturer's labeling. Do not freeze the powder or the solution.

Disposal

Unused or expired product must be disposed of according to local pharmaceutical waste regulations (e.g., drug take-back programs). Used needles, syringes, and vials are classified as sharps and must be placed immediately into a puncture-resistant sharps container for safe disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagItaly

Equivalent of Necid found in:

A-Z Index: